Global Mycetoma Treatment Market, By Type (Actinomycetoma, Eumycetoma), Antibiotic Type (Netilmicin-TS, Sulfonamides DDS (4,4 diaminodiphenyl-sulfone)), Treatment Type (Medication, Supportive Care), Route of Administration (Oral, Parenteral), Mode of Purchase (Prescription and Over the Counter), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights : Global Mycetoma Treatment Market
Global mycetoma treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a healthy CAGR of 4.90% in the above-mentioned research forecast period.
Mycetoma is a diseases which is caused by specific types of bacteria and fungi, who reside in soil and water. The bacteria might enter the body through a crack in the skin of the foot. This leads to a rise in infection, which may incur less pain but enervating masses of waste is formed under the skin that can eventually affect the underlying bone. Mycetoma is caused by the transmission of bacteria (actinomycetoma) or fungi (eumycetoma). The actual number of cases is likely substantially higher. According to the 2017 review of scientific articles between 1950 and 2017, around 17,607 cases have been reported.
Mycetoma infects people of all ages and is quite frequent in men. Primarily this disease affects the people living in rural regions of Africa, Latin America, and Asia which are located near the equator and have dry climates. People affected by mycetoma often live in remote areas where there is limited access to healthcare and medications. Mycetoma can lead to severe physical deformities that can force people to stop working and cause stigma. In the recent years maximum number of mycetoma cases has been reported in the U.S. From 1890 to 2020, less number of cases has been reported in the U.S. The treatment for mycetoma consists of the therapies which take longer time to heal, but are unaffordable, due to increased cost. The type of treatment depends on whether it is caused by bacteria (Actinomycetoma) or fungi (eumycetoma). Actinomycetoma can be treated with antibiotics. Eumycetoma is cured with long term antifungal medicine, but may not be completely effective.
The increased prevalence of mycetoma, rise in geriatric population, increased count in research and development for novel therapies, number of government initiatives, investment by R&D in pharmaceutical companies, increased demand of antibiotics for Mycetoma Treatment are predicted to drive the market growth. However, the lack of health remuneration policies, rise in cost, lack of proper sanitation, side effects associated with the use of antibiotics is expected to hinder the market growth. The rise of emerging markets in developing countries, rise of untapped opportunities, upcoming healthcare clinics, use of laser treatment to remove boils are the opportunities which are projected to bolster the market growth. The lack of expertise, rise in product (antibiotic) recalls, and use of alternatives other than antibiotics are the challenges which can tamper the market growth.
This mycetoma treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Mycetoma Treatment Market Scope and Market Size
The mycetoma treatment market is segmented on the basis of type, antibiotic type, treatment type, route of administration, mode of purchase and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the mycetoma treatment market is segmented into actinomycetoma, eumycetoma.
- On the basis of antibiotic type, the mycetoma treatment market is segmented into Netilmicin-TS, Sulfonamides DDS (4,4 diaminodiphenyl-sulfone).
- On the basis of treatment type, the mycetoma treatment market is segmented into medication, supportive care .
- On the basis of route of administration, the mycetoma treatment market is segmented into oral, parenteral.
- On the basis of mode of purchase, the mycetoma treatment market is segmented into prescription and over the counter.
- On the basis of distribution channel, the mycetoma treatment market has also been segmented into hospital pharmacies, retail pharmacies, online pharmacies and others.
Mycetoma Treatment Market Country Level Analysis
Mycetoma treatment market is analysed and market size information is provided by country, type, antibiotic type, treatment type, route of administration, mode of purchase and distribution channel as referenced above.
The countries covered in the mycetoma treatment market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America is expected to hold the largest market share due to the rising number of mycetoma cases, increased awareness among the population base about the prevention of mycetoma, affordability of antibiotics. Asia-Pacific is also expected to account for the second largest market share due to the rise in point of care diagnostics, technological advancements for treatment of mycetoma, untapped opportunities in emerging markets.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Mycetoma treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Mycetoma Treatment Market Share Analysis
Mycetoma Treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to mycetoma treatment market.
The major players covered in the mycetoma treatment market are Biochem Pharma, Zydus Cadila, GSK, Vernalis (R&D) Limited, IrisFarma, Sun Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, Galderma Laboratories, Mayne Pharma Group, Akorn, Mylan N.V., Johnson & Johnson Services, Inc, Medimetriks Pharmaceuticals, Inc , F-Hoffmann-La Roche among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-